EUVIMEDEUVIMED entdecken
Open Access

Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion

Jinhua Zhao iD, Aiping Tong iD, Jing Liu, Mingxia Xu, Peng Mi iD

Science Advances · 27.06.2025 · 11 (26)

DOI: 10.1126/sciadv.adr1728 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 27.06.2025. Verfasst von Jinhua Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Huaxi MR Research Center (HMRRC), and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, …. Hauptthemen laut MEDLINE: Immunotherapy, Membrane Proteins, Nanoparticles, Drug Carriers. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The low immunogenicity and immune escape are bottlenecks for effective tumor immunotherapy. Here, we synthesized multifunctional polymers comprising a photosensitizer and cationic and thiol derivates and engineered a galactose-installed stimulator of interferon genes (STING) agonist and programmed death ligand 1 (PD-L1) small interfering RNA (siPDL1)–encapsulated nanocarriers (cGAMP-siPDL1@GalNPs) for synergistic immunotherapy of low immunogenic tumors through stimulating robust immune responses. cGAMP-siPDL1@GalNPs efficiently delivered the drugs into cancer cells by targeting the galactose receptors to trigger photo-/redox-/pH-activated drug release. cGAMP-siPDL1@GalNPs stimulated robust antitumor immunity via STING activation and immunogenic cell death (ICD) and inhibited immune escape via knockdown of PD-L1 expression in tumors, which synergistically regulated the immune-suppressive tumor microenvironment. Upon laser irradiation, the nanocarriers efficiently eradicated primary melanoma and orthotopic triple-negative breast tumors and induced ICD effects, which synergically inhibited the distant tumor and spontaneous lung metastasis with improved survival rates. This study presents a strategy for developing nanocarriers to activate antitumor immunity and regulate immune invasion for effective immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyMembrane ProteinsNanoparticlesDrug CarriersAnimalsMiceHumansCell Line, TumorB7-H1 AntigenFemaleRNA, Small InterferingTumor MicroenvironmentNucleotides, CyclicImmunogenic Cell DeathSTING Protein

Substanzen

Membrane ProteinsB7-H1 AntigenRNA, Small InterferingDrug CarriersNucleotides, Cycliccyclic guanosine monophosphate-adenosine monophosphateSTING1 protein, humanSTING Protein

Autor:innen und Institutionen

  • Department of Radiology, Huaxi MR Research Center (HMRRC), and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
  • Department of Biotherapy and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.

ORCID-Profile: Jinhua Zhao, Aiping Tong, Peng Mi

Zitieren

APA

Zhao, J., Tong, A., Liu, J., Xu, M., & Mi, P. (2025). Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion. Science Advances, 11(26). https://doi.org/10.1126/sciadv.adr1728

Vancouver

Zhao J, Tong A, Liu J, Xu M, Mi P. Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion. Science Advances. 2025;11(26). doi:10.1126/sciadv.adr1728

BibTeX
@article{Zhao2025,
  author = {Zhao, Jinhua and Tong, Aiping and Liu, Jing and Xu, Mingxia and Mi, Peng},
  title = {Tumor-targeting nanocarriers amplified immunotherapy of cold tumors by STING activation and inhibiting immune evasion},
  journal = {Science Advances},
  year = {2025},
  volume = {11},
  number = {26},
  doi = {10.1126/sciadv.adr1728}
}
Kostenlos starten →